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OBJECTIVE — To investigate 1-year outcomes of a national diabetes prevention program in
Finland.
RESEARCH DESIGN AND METHODS — Altogether 10,149 individuals at high risk
for diabetes were identiﬁed with the Finnish Diabetes Risk Score (FINDRISC; scoring 15
points), by a history of impaired fasting glucose (IFG) or impaired glucose tolerance (IGT),
cardiovascular disease, or gestational diabetes mellitus in 400 primary health care centers.
One-year follow-up data were available for 2,798 participants who were nondiabetic at baseline
(919 men and 1,879 women, aged 56.0  9.9 and 54.0  10.7 years [mean  SD] with BMI
30.9  4.6 and 31.6  5.4 kg/m
2).
RESULTS — The incidence of diabetes was 2.0 and 1.2% in men and women with normal
glucosetoleranceatbaseline,13.5and7.4%inthosewithIFG,and16.1and11.3%inthosewith
IGT, respectively. Altogether 17.5% of the subjects lost 5% weight with no sex difference. The
relative risk of diabetes was 0.31 (95% CI 0.16–0.59) in the group who lost 5% weight, 0.72
(0.46–1.13) in the group who lost 2.5–4.9% weight, and 1.10 (0.77–1.58) in the group who
gained 2.5% compared with the group who maintained weight.
CONCLUSIONS — The FIN-D2D was the ﬁrst national effort to implement the prevention
ofdiabetesinaprimaryhealthcaresetting.Methodsforrecruitinghigh-risksubjectsweresimple
and easy to use. Moderate weight loss in this very high-risk group was especially effective in
reducing risk of diabetes among those participating in the program.
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R
andomized clinical trials have
shown that type 2 diabetes can be
prevented or at least postponed by
rather modest lifestyle changes (1–4). In
contrast to the rapidly vanishing effect of
drug treatment on prevention of diabetes
(5,6), the effects of lifestyle intervention
seem to be long lasting (7,8). The reduc-
tioninriskoftype2diabetesamonghigh-
risksubjectswas58%over3yearsboth
in the Finnish Diabetes Prevention Study
(DPS)andtheAmericanDiabetesPreven-
tion Program (DPP). This risk reduction
was achieved by frequent visits to the
clinic and individual and group counsel-
ing sessions.
The fundamental question is how the
knowledge and expertise from random-
ized clinical trials can be applied in vari-
ous clinical settings in real life. Everyday
clinicalpracticeworldwideisfacingalack
ofresourcesandisunderheavyeconomic
constraints (9,10). However, the diabetes
epidemicishereandwillovercomehealth
care resources if prevention strategies are
noturgentlyimplemented.Therefore,the
ﬁrst large-scale nationwide diabetes pre-
vention program in the world, the Na-
tional Program for the Prevention of Type
2 Diabetes (FIN-D2D), was implemented
in ﬁve hospital districts in Finland during
2003–2008, covering a population of 1.5
million (11,12). The FIN-D2D had three
major concurrent strategies: a high-risk
strategy, early treatment strategy, and
population strategy. The primary strategy
was a high-risk strategy, the aim of which
was to include prevention of diabetes and
reduction of cardiovascular risk factor
levels among high-risk individuals in
daily routines in health care centers and
occupational health care outpatient clin-
ics.Apopulationstrategyfocusedonrais-
ing awareness of diabetes and its risk
factors in the overall population, and an
earlytreatmentstrategyfocusedoncareof
diabetes in individuals who had screen-
ing-detected diabetes. This article reports
outcomes achieved in the high-risk co-
hort during a 1-year follow-up.
RESEARCH DESIGN AND
METHODS— The aim of the high-
risk strategy was to identify individuals
who have a high risk of developing type 2
diabetes and to provide them with sup-
port for lifestyle changes required to re-
ducetheirfuturerisk.Tothisend,eachof
the 400 participating primary health care
centers and occupational health care out-
patient clinics locally developed ﬂow-
charts for the implementation of
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isting resources. The ﬂowcharts were
based on the FIN-D2D project plan (11).
The rationale, design, and the detailed
protocol of the FIN-D2D have been pub-
lished earlier (11,12).
The high-risk individuals were iden-
tiﬁedusingthemodiﬁedFinnishDiabetes
RiskScore(FINDRISC),whichincludeda
question on family history of diabetes in
addition to the original seven questions
(13). The FINDRISC was used for oppor-
tunistic screening in primary health care
centers and pharmacies and at public
events such as health fairs and ice hockey
games as well as in a nationwide advertiz-
ing campaign. Screening was done by lo-
cal nurses and pharmacy personnel.
PeoplecouldalsoﬁllintheFINDRISCtest
on the Internet. Tests done at health cen-
ters and clinics were successful in bring-
ing high-risk individuals to lifestyle
counseling, whereas tests done in public
campaigns outside health care centers or
on the Internet rarely led to contacts. It
has been estimated that at least 200,000
people were screened for risk of type 2
diabetes in the project area, but the exact
number was not registered. Those who
had FINDRISC scores 15 were consid-
ered to be at high risk for diabetes, and
they were referred to the FIN-D2D (12).
Inaddition,individualswhohadahistory
of impaired fasting glucose (IFG) or im-
paired glucose tolerance (IGT), an isch-
emic cardiovascular disease event, or
gestational diabetes mellitus were consid-
ered to have a high risk for diabetes and
were referred to the FIN-D2D (12).
Altogether 10,149 individuals (3,379
men and 6,770 women) aged 18–87
years (53.6  10.9 years [mean  SD])
fulﬁlling these criteria were initially con-
tacted. Of them, 8,353 had an oral glu-
cose tolerance test (OGTT) at baseline
and 5,523 had any follow-up data. One-
year follow-up data were available for
3,880(70.3%)participants.Ofthem,638
individuals did not have an OGTT at
baseline and 444 individuals had screen-
ing-detecteddiabetesatbaselineandwere
therefore excluded from this report.
Thus,2,798individualswerenondiabetic
at baseline and had 1-year follow-up data
andtheyformthehigh-riskcohortforthis
report. The majority of the participants
were referred to the FIN-D2D based on a
FINDRISCscore15points(51%ofmen
and 57% of women). Altogether 34% of
men and 21% of women had a history of
IFG or IGT. Referral to the FIN-D2D was
based on a history of ischemic cardiovas-
cular disease in 8% of men and 2% of
women. A history of gestational diabetes
mellituswasthereasonforreferralin13%
of women. The majority of the women
with a history of gestational diabetes mel-
litus were 45 years.
The baseline visits occurred between
17 January 2004 and 28 August 2007.
The1-yearvisitswerebetween17January
2005 and 12 June 2008. The time win-
dow for 1-year visits was 9–18 months
after the baseline visits. The mean fol-
low-up time was 14 months.
In the primary health care setting,
evaluation of risk factors and glucose tol-
erance, interventions, and follow-up took
place as part of standard care. Measure-
ments were done by local nurses accord-
ing to the working instructions in the
projectplan(11).Heightwasmeasuredto
the nearest centimeter. Weight was mea-
sured to the nearest 0.1 kg with the sub-
jectinlightclothing.Waistcircumference
was measured to the nearest centimeter.
BMIwascalculatedasweightinkilograms
divided by the square of height in meters.
Blood pressure was measured twice from
the right arm with the subject in the sit-
ting position to the nearest 1 mmHg, and
the mean reading was recorded. The ex-
amination also included an OGTT with a
glucose load of 75 g and fasting and 2-h
plasma samples (14). The test started in
the morning after overnight fasting; 20%
of the tests used capillary and 80% used
venous plasma samples at baseline (15
and 85%, respectively, at 1-year follow-
up). Venous blood samples were drawn
for fasting lipid and lipoprotein determi-
nations. Plasma lipids and lipoproteins
were determined locally using enzymatic
methods. Identical examinations were
performed at baseline and at the 1-year
visit.
Glucose tolerance was classiﬁed ac-
cording to the World Health Organiza-
tion 1999 criteria (14). Individuals who
reported at baseline that they have diabe-
teswerenotincludedintheOGTT.Those
with fasting venous or capillary plasma
glucoselevels7.0mmol/lor2-hvenous
plasmaglucose11.1mmol/lor2-hcap-
illary plasma glucose 12.2 mmol/l were
classiﬁed as having diabetes. Those with
2-h venous plasma glucose 7.8 and
11.1 mmol/l or 2-h capillary plasma
glucose8.9and12.2mmol/landfast-
ing plasma glucose 7.0 mmol/l were
classiﬁed as having IGT. IFG was deﬁned
as fasting plasma glucose 6.1 but 7.0
mmol/l and 2-h venous plasma glucose
7.8 mmol/l or 2-h capillary plasma glu-
cose 8.9 mmol/l. Individuals who had
previously diagnosed or screening-
detected diabetes at baseline were ex-
cluded from this report.
Intervention visits were either indi-
vidualcounselingvisitsorgroupsessions,
during which the intervention visit form
was ﬁlled out. Counseling based on inter-
ventionexperiencesintheDPSstudy(15)
and application of different stages of
change in behavior was recommended.
Thefocusofthevisitswasonweight,meal
frequency, fat intake, quality of fat, use of
salt, ﬁber intake, use of alcohol, exercise,
or smoking, based on which topic the in-
dividual preferred. Group sessions varied
from weight maintenance groups to exer-
cise groups and lectures on diabetes and
lifestyle changes. The frequency of inter-
vention visits varied among health cen-
ters, depending on local circumstances
and resources.
Statistical methods
Statistical analyses and data management
were performed using SAS for Windows
(version 9.2). Continuous variables are
presented as mean  SD and categorical
variables are presented as percentages.
ANCOVA was used to compare
means of risk factor levels at follow-up
with means at baseline adjusting for age.
Mixed models of repeated analyses were
usedtoanalyzechangesduringfollow-up
in risk factor levels according to weight
lossgroups(weightloss5%,weightloss
2.5–4.9%, stable weight, and gained
2.5%), adjusting for age; stable weight
was used as the control group. The likeli-
hood ratio test was used to compare dif-
ferences of probabilities of incident
diabetesaccordingtoweightloss.Riskra-
tios with 95% CI were calculated by log-
binominal regression analysis to examine
the association between incident diabetes
and weight loss.
RESULTS— Baselinecharacteristicsof
the participants and the changes in risk
factor levels from baseline to the 1-year
follow-upareshowninTable1.Meanage
was 56 years in men (range 23–81 years)
and 54 years (20–84 years) in women.
The mean FINDRISC score was 17. The
majority of the participants were obese
(BMI30kg/m
2)andcentralobesitywas
common among them. Weight loss dur-
ing the 1-year follow-up was on average
1.3 kg in men and 1.1 kg in women. This
was accompanied by a 1.3-cm reduction
in the waist circumference. In addition,
blood pressure decreased, and the lipid
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rection. The decrease in systolic blood
pressure was more marked in women
than in men, whereas the decrease in di-
astolicbloodpressurewasofsimilarmag-
nitude in both sexes. Total cholesterol,
LDL cholesterol, and triglyceride levels
decreased 5–8% in men and 2–5% in
women. The increase in HDL cholesterol
levelwas2%inmenand3%inwomen.
The incidence of diabetes during a
mean follow-up of 14 months was 2.0%
among men (n  299) and 1.2% among
women (n  865) with normal glucose
tolerance. Diabetes developed in 13.5%
of men (n  230) and in 7.4% of women
(n  272) who had IFG at baseline. The
incidence of diabetes was even higher in
men (16.1%, n  254) and in women
(11.3%, n  435) who had IGT at base-
line.Thus,abnormalglucosehomeostasis
increased the risk of diabetes by six- to
ninefold in these high-risk subjects com-
paredwiththosewithnormalglucoseho-
meostasis at baseline.
The incidence of diabetes according
to loss of body weight in the whole group
is illustrated in Fig. 1. The incidence of
diabeteswasabouttwofoldhigherinmen
(2.6, 7.5, 10.4, and 10.4%, P  0.026, in
groups with weight loss of 5%, weight
loss 2.5–4.9%, stable weight, and gained
2.5%, respectively) compared with
women (1.9, 3.6, 4.8, and 6.9%, P 
0.011; data are adjusted to 50 years) in
every weight loss group. However, there
was no interaction between weight loss
and sex in regard to incidence of diabetes
(P  0.789 for interaction). The relation-
shipbetweenweightlossandincidenceof
diabeteswasalmoststepwise.Therelative
risk of diabetes was only 0.31 (95% CI
0.16–0.59), which translates to 69% risk
reduction in the group who lost 5%
weight compared with the group who
maintained weight. The relative risk was
0.72 (0.46–1.13; risk reduction of 29%)
in the group who lost 2.5–4.9% weight
and 1.10 (95% CI 0.77–1.58; risk in-
crease 10%) in the group who gained
2.5% compared with the group who
maintained weight.
Figure1—Incidenceoftype2diabetesduringthe1-yearfollow-upaccordingtoweightloss.Data
are adjusted to age 50 years. P  0.001 for the likelihood ratio test for the difference of probabil-
ities according to weight loss.
Table 1—Baseline characteristics and changes in risk factors from baseline to 1-year visit in men and women
n Baseline
Change from baseline to
one-year follow-up P value*
Men
Age (years) 919 56.0  9.9)
FINDRISC score 536 16.6  3.7
Weight (kg) 919 95.8  15.9 1.2  5.3 0.0001
BMI (kg/m
2)* 914 30.9  4.6 0.4  1.5 0.0001
Waist (cm) 888 107.3  11.4 1.3  4.9 0.0001
Systolic blood pressure (mmHg) 903 141.0  16.2 0.8  14.8 0.0932
Diastolic blood pressure (mmHg) 903 87.2  9.6 1.5  8.9 0.0001
Total cholesterol (mmol/l) 822 5.06  1.01 0.25  0.86 0.0001
HDL cholesterol (mmol/l) 814 1.25  0.33 0.02  0.22 0.0030
LDL cholesterol (mmol/l) 779 3.03  0.87 0.23  0.76 0.0001
Triglycerides (mmol/l) 811 1.80  1.19 0.11  1.12 0.0050
Women
Age (years) 1,879 54.0  10.7
FINDRISC Score 1,259 17.2  3.0
Weight (kg) 1,879 83.8  15.4 1.1  5.8 0.0001
BMI (kg/m
2) 1,872 31.6  5.4 0.4  2.1 0.0001
Waist (cm) 1,821 99.4  12.4 1.3  5.9 0.0001
Systolic blood pressure (mmHg) 1,845 138.4  17.8 1.9  14.8 0.0001
Diastolic blood pressure (mmHg) 1,845 85.3  9.2 1.6  8.4 0.0001
Total cholesterol (mmol/l) 1,658 5.24  0.95 0.14  0.79 0.0001
HDL cholesterol (mmol/l) 1,639 1.50  0.43 0.04  0.31 0.0001
LDL cholesterol (mmol/l) 1,616 3.07  0.86 0.16  0.76 0.0001
Triglycerides (mmol/l) 1,632 1.48  0.77 0.03  0.64 0.0769
Data are means  SD. *P value for ANCOVA comparing the mean at follow-up to the mean at baseline; analyses were adjusted for age.
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ing to weight loss are presented in Table
2. Altogether 17.5% of the subjects lost
5% weight. On average this meant an
8.5-kg reduction in weight and a 6.6-cm
reduction in waist circumference. During
the follow-up, 16.8% of the subjects lost
2.5–4.9% weight and 46.1% maintained
weight. Only 19.6% of the subjects
gained 2.5% weight. Men were as suc-
cessful as women in losing weight. Sys-
tolicbloodpressuredecreased4.4mmHg
anddiastolicbloodpressure3.8mmHgin
the men and women who lost 5%
weight compared with a reduction of 0.7
mmHg in systolic and 1.1 mmHg in dia-
stolic blood pressure in the group who
maintained weight (P  0.05). The de-
creaseinsystolicbloodpressurewasmore
marked in women (5.2 vs. 1.0 mmHg de-
crease, P  0.05) than in men (2.7 vs. 0.2
mmHg decrease; NS), but there was no
sex difference in the decrease in diastolic
blood pressure (women 3.7 vs. 1.2
mmHg,P0.05;men4.0vs.1.1mmHg,
P  0.05). Even a weight loss of 2.5–
4.9% was associated with a signiﬁcant re-
duction in systolic blood pressure in the
whole group (3.1 vs. 0.7 mmHg, P 
0.05). There were no sex differences in
the reduction of blood pressure levels in
the group who lost 2.5–4.9% weight.
The beneﬁcial effect of weight loss on
lipid and lipoprotein levels was mainly
seen in the group who lost 5% weight.
Levels of serum cholesterol, LDL choles-
terol, and triglycerides decreased and the
levels of HDL cholesterol increased com-
pared with those in the group who main-
tained weight. Even a weight loss of 2.5–
4.9% was associated with a reduction in
triglyceride levels although changes in
other lipid and lipoprotein levels did not
differ from those who maintained weight.
There were no sex differences in changes
in lipid and lipoprotein levels.
A weight gain of 2.5% translated to
a 4.5-kg increase in weight and 2.6-cm
increase in waist circumference. This was
associated with an increase in systolic
blood pressure and triglyceride levels.
Participants had on average 2.9 inter-
ventionvisitsduringthe1-yearfollowup.
The proportions of individuals who had
three or more, two, and one intervention
visit were 29.1, 12.9, and 26.1%, respec-
tively. Individuals who had three or more
intervention visits were more obese at
baseline than those who had only two or
one or no intervention visits (BMI 32.6 
5.6, 31.3  5.1, 30.7  4.8, and 30.9 
5.0 kg/m
2, respectively, P  0.05). How-
ever, age and the proportion of men did
not differ between the groups with differ-
ent numbers of intervention visits. The
group who lost 5% weight had on aver-
age 3.5 intervention visits, whereas those
who maintained weight had 2.9 interven-
tion visits during the follow-up (P 
0.001).Themeannumberofintervention
visits was not different in the group who
lost 2.5–4.9% weight and in the group
who gained 2.5% weight compared
with the group who maintained weight
(3.0 and 2.5 vs. 2.9, respectively).
Altogether 32.0% of the subjects had
norecordedinterventionvisitsduringthe
follow-up. Among participants who had
intervention visits, 51% had individual
counseling visits only, 13% attended
group sessions only, and 10% partici-
pated both in individual and group visits.
Thetypeofvisitswasnotrecordedin26%
of individuals who had intervention
visits.
CONCLUSIONS — The FIN-D2D is
the ﬁrst national effort to implement the
preventionofdiabetesinaprimaryhealth
care setting. The results of this study de-
pict what can be achieved by such a big
undertaking in terms of diabetes preven-
tion and reduction of cardiovascular risk
factors. Methods for recruiting high-risk
subjects in this study were simple and
easy to use. Experiences derived from the
DPS study were applied to the interven-
tion visits.
The incidence of diabetes during a
mean follow-up of 14 months was excep-
tionally high in subjects with IFG or IGT
inthisstudy.Inpreviousstudies,progres-
sion from IGT to diabetes has varied be-
tween 5 and 6% per year (1,16,17) and
from IFG to diabetes between 3 and 6%
per year (16,17). However, in the Anglo-
Danish-Dutch Study of Intensive Treat-
ment in People with Screen Detected
Diabetes in Primary Care (ADDITION)
study, progression rates were particularly
high in the 1st year of follow-up, namely
16.0% for IFG and 23.8% for IGT, which
are closer to the numbers observed in this
study (18). Thus, screening strategies for
high-risksubjectsusedintheFIN-D2Das
well as in the ADDITION study tend to
identify subjects who have a very high
early conversion rate from abnormal glu-
cose tolerance to diabetes. The conver-
sionratefromnormalglucosetoleranceto
Table 2—Changes in risk factors from baseline to 1-year visit according to weight loss
Weight loss 5% Weight loss 2.5–4.9% Stable weight* Gained 2.5% ANCOVA P
value† n Mean  SD n Mean  SD n Mean  SD n Mean  SD
Weight (kg) 490 8.5  6.5‡§ 471 3.1  0.9‡§ 1,290 0.1  1.2 546 4.5  3.7‡§ 0.001
BMI (kg/m
2) 489 3.0  2.3‡§ 470 1.1  0.3‡§ 1,285 0.04  0.46 541 1.6  1.0‡§ 0.001
Waist (cm) 477 6.6  6.1‡§ 449 2.7  4.2‡§ 1,258 0.4  4.2 525 2.6  5.1‡§ 0.001
Systolic blood pressure
(mmHg) 480 4.4  14.4‡§ 464 3.1  15.4‡§ 1,267 0.7  14.5 536 0.5  15.1‡ 0.001
Diastolic blood pressure
(mmHg) 480 3.8  8.4‡§ 464 2.2  8.3 1,267 1.1  8.4 536 0.1  8.7 0.001
Lipids (mmol/l)
Total cholesterol 438 0.35  0.78 411 0.23  0.92 1,148 0.15  0.78 482 0.02  0.81‡§ 0.001
HDL cholesterol 430 0.10  0.25‡§ 408 0.05  0.29 1,138 0.02  0.27 476 0.01  0.31 0.001
LDL cholesterol 420 0.33  0.71‡§ 400 0.22  0.89 1,111 0.17  0.72 463 0.07  0.74‡ 0.001
Triglycerides 430 0.29  0.66‡§ 406 0.15  0.95‡§ 1,133 0.01  0.76 473 0.12  0.95‡§ 0.001
*Weight loss 2.5% or weight gain 2.5%. †ANCOVA for overall and pairwise comparisons of mean changes between the groups; analyses were adjusted for age
(‡) or for age and sex (§). ‡Pairwise comparisons between groups, P  0.05 (stable weight served as the reference group). §Pairwise comparisons between groups,
P  0.05 (stable weight served as the reference group).
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higher than that in some previous studies
(16,19)andfour-tosixfoldhigherthanin
the Inter99 study (17).
Weight loss of 5% was accompa-
nied by a 69% reduction in the risk of
diabetes over 1 year compared with that
in subjects who maintained weight. This
is an unexpectedly high decrease in dia-
betes risk. The risk reduction was 58%
over 3 years in the DPS and DPP studies
(1,2). Our results emphasize that moder-
ate weight loss in this very high-risk
group representing early converters is es-
pecially effective in reducing risk of dia-
betes or at least postponing diabetes.
Longer follow-up is needed to see
whether this effect will last over time.
The average weight loss during the
1-year follow-up was 1 kg. This is very
modest compared with a 4.2-kg weight
loss at 1 year in the intervention group of
the DPS study (1). However, even this
fairly small weight loss was accompanied
by multiple beneﬁcial changes in cardio-
vascular risk factors. It is not known
whether these changes were mainly due
to weight loss or were explained by
changes in diet and exercise level. More-
over, 17.5% of the participants lost 5%
weight.Thisis50%oftheproportionof
individuals reaching 5% weight loss
during the 1st year in the placebo groups
in large randomized weight reduction tri-
als (20,21) and implies that individuals
participating in a diabetes prevention
program are motivated to make lifestyle
changes. Weight loss of 5% was associ-
ated with marked beneﬁcial changes in
blood pressure and lipid and lipoprotein
levels, which were of the same magnitude
as in the intervention groups of the DPS
(1) and DPP (22) studies.
From the perspectives of feasibility
and economics, it is important that the
lifestyle changes and risk reduction of di-
abetes achieved in this study required a
very modest number of visits to health
centersoroccupationalhealthcareoutpa-
tient clinics. At baseline, subjects had one
or two visits to the nurse for measure-
ments and to collect data on diet and ex-
ercise. This baseline interview was
designed to serve as a mini-intervention
in addition to data collection. In addition,
thesubjectshadonaverage2.9intervention
visits over 1 year. Those who lost 5%
weight had on average 3.5 intervention vis-
its. It is possible that the real number of in-
tervention visits was somewhat larger,
because the intervention visit form was not
always ﬁlled out during group sessions.
Only 50% of the total cohort had any
follow-up data. The ﬁrst loss to follow-up
occurred after screening; only 78% of the
screened high-risk subjects had an
OGTT. The second loss to follow-up oc-
curred after the OGTT. Only 69% of sub-
jects who had an OGTT at baseline had
any follow-up data. These data reﬂect a
real-life setting and the difﬁculty in fol-
lowing up on patients in primary health
care settings. Altogether 70% of the co-
hortparticipatinginfollow-uphad1-year
follow-up data available.
Despite some weaknesses, this is the
largest study so far on implementation of
screening and prevention of diabetes
among high-risk individuals in the pri-
mary health care setting. Because the
magnitude of the diabetes epidemic is so
overwhelming, cross-disciplinary health
promotion activities that lead to lifestyle
changes at the population level are
needed to combat it. A good example of
an effective strategy is the North Karelia
project launched in 1972, which raised
public awareness of the importance of
lifestyle behaviors in the whole of Fin-
land, contributing to a marked decrease
in coronary heart disease and stroke mor-
tality (23,24).
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